

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 9, 2006

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

1-10730

04-2882273

*(State or other jurisdiction
of incorporation)*

*(Commission
File Number)*

*(I.R.S. Employer
Identification No.)*

400 Wood Road

02184

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 **OTHER EVENTS**

On August 9, 2006, the Board of Directors authorized the Company to repurchase up to \$40 million of Haemonetics' common stock. Repurchases under this authorization will occur under a 10b5-1 plan.

Item 9.01 **FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits

Exhibit 99.1 – The Company's press release dated August 10, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

(Registrant)

Date: August 10, 2006

/s/ Ronald J. Ryan

Ronald J. Ryan,
Vice President and
Chief Financial Officer

Haemonetics Announces Stock Repurchase Program

PR Newswire -- August 10, 2006

BRAINTREE, Mass., Aug. 10 /PRNewswire-FirstCall/ -- Haemonetics Corporation announced today that its Board of Directors has authorized the Company repurchase up to \$40 million of Haemonetics' common stock. Repurchases will occur under a 10b5-1 plan.

Ronald A. Matricaria, Haemonetics' Chairman, said, "Haemonetics remains committed to its strategy of expanding the business. With our strong cash balance and anticipated future cash flows, we can continue to create shareholder value by both investing in the business as well as returning cash to our shareholders."

Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics' products and markets, visit its web site at <http://www.haemonetics.com>.

This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

CONTACT:

Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

fallon@haemonetics.com

SOURCE Haemonetics Corporation

-0- 08/10/2006

/CONTACT: Julie Fallon of Haemonetics, +1-781-356-9517, Alternate Tel., +1-617-320-2401, fallon@haemonetics.com//Web site: <http://www.haemonetics.com/>

(HAE)